Paper40939764
Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.
Okereke LC and 3 others. Math Biosci, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control. Papers, record 40939764. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40939764
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neurotoxicity Syndromes | Major topic |
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Tumor Burden | |
| Humans | |
| Computer Simulation | |
| Treatment Interruption | |
| Precision Medicine |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA240589 | NCI NIH HHS | United States | R01CA240589 | PubMed | NIH RePORTER |
| R01 CA276540 | NCI NIH HHS | United States | R01CA276540 | PubMed | NIH RePORTER |
| U01 CA253540 | NCI NIH HHS | United States | U01CA253540 | PubMed | NIH RePORTER |
References99
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12894998 | Molecular mechanisms of chemotherapy-induced hair loss. | J Investig Dermatol Symp Proc | 2003 | https://conductscience.org/library/papers/12894998 | PubMed |
| 2 | 23850479 | Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. | J Theor Biol | 2013 | https://conductscience.org/library/papers/23850479 | PubMed |
| 3 | 25445718 | The double-edged sword: Neurotoxicity of chemotherapy. | Blood Rev | 2015 | https://conductscience.org/library/papers/25445718 | PubMed |
| 4 | 16322118 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. | Ann Oncol | 2006 | https://conductscience.org/library/papers/16322118 | PubMed |
| 5 | 26775862 | Dynamics and control of a mathematical model for metronomic chemotherapy. | Math Biosci Eng | 2015 | https://conductscience.org/library/papers/26775862 | PubMed |
| 6 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 7 | 32143730 | A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. | Trials | 2020 | https://conductscience.org/library/papers/32143730 | PubMed |
| 8 | 33434599 | The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. | J Control Release | 2021 | https://conductscience.org/library/papers/33434599 | PubMed |
| 9 | 27864095 | Optimization of an in vitro chemotherapy to avoid resistant tumours. | J Theor Biol | 2017 | https://conductscience.org/library/papers/27864095 | PubMed |
| 10 | 33239688 | Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. | Sci Rep | 2020 | https://conductscience.org/library/papers/33239688 | PubMed |
| 11 | 31619372 | Embracing the complexity: Older adults with cancer-related cognitive decline-A Young International Society of Geriatric Oncology position paper. | J Geriatr Oncol | 2020 | https://conductscience.org/library/papers/31619372 | PubMed |
| 12 | 15958110 | Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. | Intern Med J | 2005 | https://conductscience.org/library/papers/15958110 | PubMed |
| 13 | 28802891 | Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | Clin Lymphoma Myeloma Leuk | 2017 | https://conductscience.org/library/papers/28802891 | PubMed |
| 14 | 35776787 | Measuring competitive exclusion in non-small cell lung cancer. | Sci Adv | 2022 | https://conductscience.org/library/papers/35776787 | PubMed |
| 15 | 29148865 | Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. | Pediatr Hematol Oncol | 2017 | https://conductscience.org/library/papers/29148865 | PubMed |
| 16 | 36699654 | Cancer treatment induces neuroinflammation and behavioral deficits in mice. | Front Behav Neurosci | 2022 | https://conductscience.org/library/papers/36699654 | PubMed |
| 17 | 35557664 | The 18-kDa Translocator Protein PET Tracers as a Diagnostic Marker for Neuroinflammation: Development and Current Standing. | ACS Omega | 2022 | https://conductscience.org/library/papers/35557664 | PubMed |
| 18 | 24889111 | Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. | Nat Commun | 2014 | https://conductscience.org/library/papers/24889111 | PubMed |
| 19 | 23666914 | Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23666914 | PubMed |
| 20 | 28209166 | Intra-tumor heterogeneity from a cancer stem cell perspective. | Mol Cancer | 2017 | https://conductscience.org/library/papers/28209166 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40939764
GET https://conductscience.org/api/papers/v1/40939764/references?page=2